Ferrer Internacional Company Profile
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the competitive landscape for FERRER INTERNACIONAL, and when can generic versions of FERRER INTERNACIONAL drugs launch?
FERRER INTERNACIONAL has one approved drug.
There are three US patents protecting FERRER INTERNACIONAL drugs.
There are forty-four patent family members on FERRER INTERNACIONAL drugs in twenty-five countries and seven supplementary protection certificates in seven countries.
Summary for Ferrer Internacional
| International Patents: | 44 |
| US Patents: | 3 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
Drugs and US Patents for Ferrer Internacional
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ferrer Internacional | XEPI | ozenoxacin | CREAM;TOPICAL | 208945-001 | Dec 11, 2017 | RX | Yes | Yes | 9,180,200 | See Plans and Pricing | Y | See Plans and Pricing | |||
| Ferrer Internacional | XEPI | ozenoxacin | CREAM;TOPICAL | 208945-001 | Dec 11, 2017 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | |||||
| Ferrer Internacional | XEPI | ozenoxacin | CREAM;TOPICAL | 208945-001 | Dec 11, 2017 | RX | Yes | Yes | 6,335,447 | See Plans and Pricing | Y | See Plans and Pricing | |||
| Ferrer Internacional | XEPI | ozenoxacin | CREAM;TOPICAL | 208945-001 | Dec 11, 2017 | RX | Yes | Yes | 9,399,014 | See Plans and Pricing | See Plans and Pricing | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Ferrer Internacional Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Poland | 2344130 | See Plans and Pricing |
| South Korea | 20160116353 | See Plans and Pricing |
| Australia | 2009305360 | See Plans and Pricing |
| South Korea | 101682256 | See Plans and Pricing |
| Brazil | 9909456 | See Plans and Pricing |
| China | 1299356 | See Plans and Pricing |
| Slovenia | 2344130 | See Plans and Pricing |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Ferrer Internacional Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2344130 | 122017000073 | Germany | See Plans and Pricing | PRODUCT NAME: OZENOXACIN; NAT. REGISTRATION NO/DATE: 97303.00.00 20170803; FIRST REGISTRATION: BELGIEN BE509591 20170517 |
| 2344130 | 132017000093887 | Italy | See Plans and Pricing | PRODUCT NAME: OZENOXACIN(DUBINE); AUTHORISATION NUMBER(S) AND DATE(S): ES/H/414/01/DC, 20170519;045237017, 20170711 |
| 2344130 | 1790031-7 | Sweden | See Plans and Pricing | PRODUCT NAME: OZENOXACIN; NAT. REG. NO/DATE: 54608 20170622; FIRST REG.: BE ES/H/414/01/DC 20170519 |
| 2344130 | 2017/038 | Ireland | See Plans and Pricing | PRODUCT NAME: OZENOXACIN; NAT REGISTRATION NO/DATE: PA1744/003/001 20170616; FIRST REGISTRATION NO/DATE: ES/H/414/01/DC 20170519 |
| 2344130 | 300884 | Netherlands | See Plans and Pricing | PRODUCT NAME: OZENOXACIN; REGISTRATION NO/DATE: ES/H/414/1/DC 20170519 |
| 2344130 | 2017C/031 | Belgium | See Plans and Pricing | PRODUCT NAME: OZENOXACINE; AUTHORISATION NUMBER AND DATE: BE509591 20170519 |
| 2344130 | C201730036 | Spain | See Plans and Pricing | PRODUCT NAME: OZENOXACINO; NATIONAL AUTHORISATION NUMBER: 82357-ES/H/0414/001/DC; DATE OF AUTHORISATION: 20170830; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): ES/H/414/01/DC; DATE OF FIRST AUTHORISATION IN EEA: 20170519 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
